瑞舒伐他汀联合丁苯酞治疗对脑梗死患者认知功能、凝血功能的影响

Effects of Rosuvastatin Combined with Butylphthalide on Cognitive Function and Coagulation Function in Patients with Cerebral Infarction

目的分析脑梗死患者应用瑞舒伐他汀联合丁苯酞的临床治疗效果,探讨对患者认知功能与凝血功能的影响。方法选取2019年6月—2021年6月于该院进行诊治的56例脑梗死患者,根据奇偶数分组方式将研究对象划分为对照组与研究组,每组28例,对照组患者采用瑞舒伐他汀治疗,研究组采用患者瑞舒伐他汀联合丁苯酞胶囊治疗,比较两组患者临床药物治疗的效果、认知功能、神经功能、凝血功能以及不良反应。结果研究组患者MMSE评分为(27.42±2.47)分,NIHSS评分为(11.75±2.49)分明显优于对照组,差异有统计学意义(t=3.194、6.064,P<0.001);研究组凝血酶原时间、凝血酶时间以及活化部分凝血酶时间分别为(16.24±1.31)、(20.76±1.33)、(39.96±4.15)s,明显优于对照组,差异有统计学意义(t=6.608、8.031、4.847,P<0.001);研究组患者临床治疗有效率为96.42%,显著高于对照组,差异有统计学意义(χ^(2)=4.766,P=0.029);研究组患者不良反应发生率为14.28%,对照组为17.85%,差异无统计学意义(P>0.05)。结论脑梗死患者应用瑞舒伐他汀联合丁苯酞治疗,其临床治疗效果显著提升,能够有效改善患者认知功能和凝血功能,降低患者神经功能损伤程度,有助于促进患者康复,值得在临床中大力推荐。

Objective To analyze the clinical effect of rosuvastatin combined with butylphthalide in patients with cerebral infarction,and to explore the effect on cognitive function and coagulation function of patients.Methods 56 patients with cerebral infarction who were diagnosed were selceted in the hospital from June 2019 to June 2021.According to the odd-even grouping method,the research subjects were divided into the control group and the study group,with 28 cases in each group.The control group was treated with Rosuvastatin,and the study group was treated with Rosuvastatin combined with Butylphthalide capsules.The clinical drug treatment effect,cognitive function,neurological function,coagulation function and adverse reaction were compared between the two groups.Results The MMSE score of the patients in the study group was(27.42±2.47)points,and the NIHSS score was(11.75±2.49)points,which were significantly better than those of the control group,and the difference was statistically significant(t=3.194,6.064,P<0.001);the prothrombin time,thrombin time and activated partial thrombin time of the study group were(16.24±1.31)s,(20.76±1.33)s,(39.96±4.15)s,were significantly better than those in the control group,with statistical differences(t=6.608,8.031,4.847,P<0.001).The clinical effect was 96.42%in the study group,which was significantly higher than that in the control group,and the difference was statistically significant(χ^(2)=4.766,P=0.029).The incidence of adverse reactions was 14.28%in the study group and 17.85%in the control group,and the difference was not statistically significant(P>0.05).Conclusion The clinical treatment effect of rosuvastatin combined with butylphthalide in patients with cerebral infarction is significantly improved,which can effectively improve the cognitive function and coagulation function of patients,and reduce the degree of neurological damage in patients.It helps to promote the recovery of patients and is worthy of strong recommendation in clinical practice.